Robert H. Lurie Comprehensive Cancer Center of Northwestern University
676 North St. Clair Street, 21st Floor, Chicago, IL 60611 - USA Maggie Daley Center for Women’s Cancer Care, Prentice Women's Hospital 250 E Superior, 4th Floor, Chicago, IL 60611 - USA
About Network Member
First established at Northwestern University in 1974, the center was dedicated as the Robert H. Lurie Cancer Center of Northwestern University in 1991 through a gift of endowment from Ann and Robert H. Lurie. The center’s title was modified in 1997, when the National Cancer Institute (NCI) awarded the Lurie Cancer Center the “comprehensive” designation, reflecting the center’s dedication to the highest standards of cancer research, patient care, education, and community outreach.
Today, the Lurie Cancer Center is one of only 41 NCI-designated “comprehensive” cancer centers in the nation. In addition, the Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 25 of the world’s leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer. It also is part of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities.
The Lurie Cancer Center is affiliated with four teaching hospitals in Chicago — Northwestern Memorial Hospital, Ann & Robert H. Lurie Children’s Hospital of Chicago, the Rehabilitation Institute of Chicago, and the Jesse Brown Veteran’s Affairs Medical Center – treating more than 10,000 new cancer cases each year.
Website: Robert H. Lurie Comprehensive Cancer Center
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337
A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)